Companies working on inhaled version of PAH treatment ralinepag
WHY IT MATTERS
If approved, inhaled ralinepag could offer PAH patients a non-invasive alternative to oral tablets, potentially improving drug delivery directly to affected lung tissue and reducing systemic side effects.
Two companies are working together to create a new way to take a PAH medicine. Instead of swallowing a pill, patients would inhale a dry powder that goes straight to the lungs. This gives people with pulmonary arterial hypertension another option for how they receive their treatment.
Mannkind said it is creating an inhaled formulation of ralinepag, an experimental oral pulmonary arterial hypertension (PAH) treatment, for developer United Therapeutics. The inhaled version, ralinepag DPI, will be a dry powder that delivers the drug directly to the lungs, providing an alternative to the tablet formulation. The announcement comes on the heels of positive data […] The post Companies working on inhaled version of PAH treatment ralinepag appeared first on Pulmonary Hypertensi